Anti-DSG2 antibodies likely explain the cardiac inflammation frequently identified in ARVC and may represent a new therapeutic target (Chatterjee et al., 2018). This evidence concerns the gene DSG2 and arrhythmogenic right ventricular cardiomyopathy.